Key result
Tirzepatide is linked to ~34% lower incident dementia risk versus SGLT2 inhibitors in diabetes.
Why the study?
While SGLT2 inhibitors and GLP-1 receptor agonists may reduce dementia risk, the effect of the dual GLP1/GIP receptor agonist tirzepatide on dementia outcomes remains unknown.
Does initiation of tirzepatide reduce the 2-year risk of incident dementia compared with semaglutide and SGLT2 inhibitors in adults with type 2 diabetes?
Cohort (n=28,924)
Propensity-score matched (1:1 using nearest-neighbour greedy matching with a caliper of 0.25 times the standard deviation)
Yes
Does initiation of tirzepatide reduce the 2-year risk of incident dementia compared with semaglutide and SGLT2 inhibitors in adults with type 2 diabetes?
In this large real-world target trial emulation of patients with type 2 diabetes, initiation of tirzepatide was associated with a significantly lower 2-year risk of incident dementia and all-cause mortality compared with both semaglutide and SGLT2 inhibitors, alongside lower MACE compared with SGLT2 inhibitors.
Answers are grounded in this paper and cite their sources.
These observational associations should not yet change prescribing; leaves open confirmation of dementia risk reduction in randomized trials.
AIMS: Evidence suggests sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists may reduce the onset/progression of dementia. The effect of the dual GLP1/GIP receptor agonist tirzepatide on dementia outcomes remains unknown. We compared tirzepatide, semaglutide and SGLT2-i in relation to incident dementia in patients with type 2 diabetes. METHODS: Three target trial emulations (TTE) were conducted using real-world data from the TriNetX global federated network: TTE1: tirzepatide vs. SGLT2-i, TTE2: semaglutide vs. SGLT2-i and TTE3: tirzepatide vs. semaglutide. Eligible adults with type 2 diabetes without dementia at baseline were included. Follow-up was two years. First diagnosis of dementia, MACE, and all-cause mortality were analysed using survival analysis after propensity score matching. RESULTS: After matching, TTE1 included 14,462 patients; TTE2, 57,959; TTE3 12,246. Tirzepatide was associated with a lower risk of dementia versus semaglutide (HR 0.69, 95% CI 0.48-0.99, p = 0.04) and SGLT2-i (HR 0.66, 95% CI 0.47-0.93, p = 0.02), and lower mortality (HR 0.72, 95% CI 0.58-0.90, p < 0.01; HR 0.29, 95% CI 0.23-0.37, p < 0.01). Tirzepatide and semaglutide reduced MACE vs SGLT2-i. CONCLUSIONS: Tirzepatide is associated with a lower risk of dementia versus semaglutide and SGLT2-i in type 2 diabetes. Our findings are hypothesis generating, requiring confirmation in randomised controlled trials.
No takes yet. Share an insight, caveat, or question.
Younis et al. (2026) conducted a cohort in Type 2 diabetes without dementia at baseline (n=28,924). Tirzepatide vs. SGLT2 inhibitors (TTE1) and Semaglutide (TTE3) was evaluated on First-time diagnosis of incident dementia (composite of Alzheimer's disease, vascular dementia, or mixed dementia) (HR 0.66, 95% CI 0.47-0.93, p=0.02). Tirzepatide was associated with a lower risk of incident dementia compared to SGLT2 inhibitors and semaglutide over 2 years in type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: